A Proven Medicine; A New Prescription Form; A Trustworthy Option to Treat Depression

Good mental health is a state of wellbeing everyone should be able to enjoy.

Globally, an estimated 5% of adults suffer from depression, according to the World Health Organisation (WHO), which states approximately 280 million people worldwide have depression(1), between 2-5% of whom have drug resistant depression.

Neurocentrx is a growing biopharma company and has created new oral formulations of therapeutic ketamine to treat severe depression, bipolar depression and other mental health conditions.

Clinical studies using injectable ketamine have shown this therapy can be a safe and effective treatment for depressed patients, even after other medications have failed.

Our patented, abuse deterrent Keticap® capsules are currently in research and development. We aim for the FDA to approve and authorise Keticap as the 1st oral form of this safe and effective agent to be made available by standard prescription, providing doctors and their patients with a new trustworthy, cost-effective medication to treat depression.

We believe that Keticap can improve the lives of many patients suffering from depression and other mental health conditions – helping them to feel better, happier and more fulfilled.

Reference

1. Institute of Health Metrics and Evaluation. Global Health Data Exchange (GHDx).  https://vizhub.healthdata.org/gbd-results/ (Accessed 4 March 2023).